The Indian pharmaceutical market is expected to grow 8-9 per cent year-on-year in FY26, according to a report on Monday.
The report by India Ratings and Research (Ind-Ra) said the growth in the sector will be at 7.5-8.0 per cent year-on-year for FY25.
This is “against 6.5 per cent year-on-year in FY24 and 9.9 per cent YoY growth in FY23,” said Krishnanath Munde, associate director at India Ratings and Research.
In February, the pharma market delivered revenue growth of 7.5 per cent year-on-year. This growth was driven by price growth (5.2 per cent YoY) and new launches (2.4 per cent YoY), while volume growth remained muted at negative 0.2 per cent YoY, the report said.
The sector reported growth at an average of 7.3 per cent year-to-date (YTD) in FY25. This was led by price growth (5.5 per cent), new launches growth (2.7 per cent), and volume growth.
Further, the moving annual total (MAT) — or the 12-month rolling sales of overall pharma products — saw an 8.1 per cent surge in February, the report said. Cardiac therapies outperformed growth in the pharma market with 10.8 per cent growth in MAT and a 13.7 per cent increase in monthly market share. This was followed by gastroenterology, neurology/Central Nervous System, and dermatology.
On the other hand, anti-infectives, respiratory, and gynaecology therapies saw weaker growth in February, the report said.
Meanwhile, another recent report showed that the pharma sector in the country is witnessing rapid production growth. The Indian pharma sector has grown at 8 per cent CAGR and has also seen a 9 per cent increase in export rates in 2024, according to the report by McKinsey & Company.
Expanding its capabilities in APIs and biotechnology, the sector has grown at 8 per cent CAGR, twice the global average. The country also emerged as the world’s largest supplier of generic medicines, with a 9 per cent pharma export growth rate, nearly double the global average, the report said.
(Inputs from IANS)
